SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?


To: Rande Is who wrote (4168)3/10/1999 2:48:00 PM
From: Archie Goodwin  Read Replies (1) | Respond to of 57584
 
BPLX... any thoughts Rande....some recent information

Bio Plexus, Inc. Ticker: BPLX Page 1 of 10
Complete Financials: September 1998 Exchange NASD
FY END DEC
ISSUE DATA (03/05/99) PER SHARE DATA RATIOS
Price $ 2.31 EPS (TTM) $ -0.32 P/E (TTM) NM
52W High $ 5.63 Div. Rate $ 0.00 Yield 0.00 %
52W Low $ 1.56 Book Value $ 0.27 Price/Book 8.63
Shrs Out 12.28 Mil Cash $ 0.04 ROE (TTM) -103.97 %
Float 9.80 Mil Rev (TTM) $ 0.63 ROA (TTM) -33.10 %
Mon. Vol 0.57 Mil Curr. Ratio 0.82
Beta -0.63 LT Dbt/Eqty 0.73
BRIEF: Bio Plexus, Inc. designs, develops, manufactures and
sells safety medical products, focusing on its Punctur-Guard
series of safety blood collection needles. For the 9 months
ended 9/30/98, revenues rose 58% to $6.9M. Net loss applic.
to Common fell 87% to $1.3M. Revenues reflect progress
payments by JJMI on the capital equipment project and the
recognition of deferred revenue for the I.V. catheter.
Lower loss also reflects lower work force & financing costs.


9/95, Co. issd. 1.5M shs. @ $11.25. All fncls. prior to IPO
are proforma. FY'91, Co. chg. FY-end from AUG. 12/97 B/S
is reclassified.

DIVIDENDS EMPLOYEES
Last Dividend Decl. $ NA # Employees 72
Last Div Ex-Date NA Sales/Employee (TTM) 105,208
Last Div Pay Date NA Net. Income/Empl.(TTM) NM
Copyright (c) 1999, Market Guide Inc., All rights reserved (more)

Bio Plexus, Inc. EQUITY, OFFICERS & ADDRESS Page 5 of 10
Common Stock no Par, 11/98, 18M auth., 12,279,165 issd.
Insiders control approx. 13%. Herman Gross owns approx. 7%.
IPO: 6/94, 1,425,000 shares @ $10 by Advest, Inc. (As of
12/97) LTD: $673K @ 8%, $1.3M @ 9%, $3.4M in capital
leases. 10/97, 2.5M Prfrd. Stk. conv. into 3.8M Comm. Stk.


OFFICERS: L.C. Krampert, Chmn., R.L. Higgins, Pres./CEO/
CAO, K.A. Cady, VP-Fin./CFO, C.R. Sahi, VP/Treas., N.S.
Lautenbach, Secy. TRANSFER AGENT: First National Bank of
Boston. Company incorporated 1987 in CT. Direct inquiries
to: Christina H. Tamburro, Shareholder Relations Manager.
ADDRESS & PHONE NUMBERS
Bio Plexus, Inc.
129 Reservoir Road
Vernon, CT 06066
PHONE: (860) 870-6112
FAX: (860) 870-6118

VERNON, Conn.--(BW HealthWire)--March 10, 1999--The move toward
mandating safe needles for health care workers continues to grow. As
published on the front page of yesterday's edition of The Wall Street
Journal, the Service Employees International Union (SEIU) has
spearheaded a lobbying effort for safe needles with 18 states and the
District of Columbia. They are aiming for laws that mirror the one
passed by the California legislature last fall. The California law
requires that hospitals use needles designed to protect the workers
from accidental needlesticks.
"The SEIU's legislative campaign is building the momentum for a
nationwide mandate of safety needles," said Tom Sutton, EVP of
Marketing and Sales at Bio-Plexus, Inc. "Healthcare workers shouldn't
have to risk their lives in caring for others. Mandating the use of
safety needles will have a tremendous impact in preventing accidental
needlesticks. If the trend continues, as it appears it will,
conventional, 'unsafe' needles will become obsolete," Sutton
concluded.
Bio-Plexus, Inc. (NASDAQ:BPLX), designs, develops, manufactures,
markets, and holds U.S. and international patents on safety medical
needles and other products under the PUNCTUR-GUARD(R) and DROP-IT(R)
brand names. In a Centers for Disease Control study, Punctur-Guard
Blood Collection Needles were found to reduce the rate of accidental
needlesticks among healthcare workers by 76%, the highest rate of any
device studied. Accidental needlesticks number more than 950,000 per
year in the United States and can result in the transmission of deadly
diseases including HIV and Hepatitis B and C.

This thing spiked from roughly $2 to $4 when California legislated the safety needle back in September.

regards

A.G.



To: Rande Is who wrote (4168)3/10/1999 3:02:00 PM
From: Jason W  Read Replies (1) | Respond to of 57584
 
Rande,
I found the CDNW/NTKI post very interesting...
Just a thought though..It seems TOO many people feel a major run will occur after the merger takes place. I feel comfortable when it comes from someone like yourself, but not too many others. I hope this isn't a case of buy on rumor, sell on news. If everyone truly anticipates a run-up, the price would be rising dramatically already. That's not happening. The volume isn't even significant.(320k today) My opinion is that the shorts are covering to protect profits, and not give them back when/if the merger does inflate the stock.
I look for a short term run-up in price, followed by a pullback. I believe the only real pop will occur when the merged companies are bought out. When that will happen, I have no clue.
If anyone would like to predict who will buy them, and when, I'd love to hear it.
** I am long CDNW and NTKI.
Jason W